Moderna recently announced that its COVID-19 vaccine booster increased neutralizing activity levels against the Omicron variant.
The currently authorized 50-microgram booster of mRNA-1273...
Kite, a Gilead Company, recently announced positive primary results from a Phase 2 study of Yescarta in patients with high-risk large B-cell lymphoma (LBCL).
The global ZUMA-12 study enrolled 42...
Johnson & Johnson recently announced longer-term results from the Phase 1b/2 study evaluating the safety and efficacy of its T-cell (CAR-T) therapy for patients with relapsed or refractory multiple...
Johnson & Johnson recently announced preliminary results from an independent study, which showed that a booster shot of its COVID-19 vaccine increased both antibody and T-cell responses.
In the...
The Strategic Advisory Group of Experts on Immunization (SAGE) for the World Health Organization (WHO) recently supported using Johnson & Johnson’s COVID-19 vaccine booster shot in...
GSK recently welcomed the decision of the Gavi Board to fund the procurement and introduction of malaria vaccines into routine child immunization programs in eligible countries.
GSK developed its...
Pfizer and BioNTech recently announced that their COVID-19 vaccine neutralized the SARS-CoV-2 Omicron variant after three doses.
A month after receiving the booster vaccination, sera obtained...
FDA recently approved imaging drug Cytalux to assist surgeons in identifying ovarian cancer lesions.
Cytalux is approved for use in adult patients with ovarian cancer to help identify...
Moderna recently dosed the first participant in the Phase 2/3 study of its mRNA respiratory syncytial virus (RSV) vaccine candidate.
mRNA-1345 is an RSV vaccine for a prefusion F glycoprotein,...
FDA recently expanded the emergency use authorization (EUA) for a booster dose of the Pfizer-BioNTech COVID-19 vaccine to include individuals 18 years of age and older.
Caregivers can administer the...
FDA recently approved PharmaEssentia’s injection to treat adults with polycythemia vera, a rare blood disease that causes overproduction of red blood cells.
The monopegylated, long-acting...
Bristol Myers Squibb recently announced that Opdivo plus chemotherapy significantly improved event-free survival (EFS) in patients with resectable stage IB to IIIA non-small cell lung cancer...
Eli Lilly and Company recently announced that Jardiance slowed kidney function decline in adults with heart failure with left ventricular ejection fraction (LVEF) over 40 percent regardless of chronic...
Johnson & Johnson recently entered into an agreement with the US government and Gavi, the Vaccine Alliance, to allow access to its single-shot COVID-19 vaccine through the COVAX Humanitarian...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently recommended the approval of Roche’s COVID-19 antibody combination, Ronapreve.
CHMP...
Merck and Ridgeback Biotherapeutics recently announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) authorized their COVID-19 treatment for adults.
The UK’s...
Pfizer recently announced that its COVID-19 treatment, PAXLOVID, reduced hospitalization and death in high-risk adults with coronavirus by 89 percent compared to placebo.
In the Phase 2/3...
Eli Lilly and Company recently announced that tirzepatide elicited superior A1C and body weight reductions from baseline in adults with type 2 diabetes with increased cardiovascular risk.
Data...
FDA recently granted emergency use authorization to Pfizer and BioNTech’s COVID-19 vaccine for children five through 11 years of age.
The agency based its decision on data from a Phase 2/3...
Bristol Myers Squibb recently announced interim results from a Phase 3 open-label extension trial, which showed the long-term efficacy and safety profile of Zeposia in patients with relapsing forms of...
